公开(公告)号：US11993661B2

公开(公告)日：2024-05-28

申请号：US17253589

申请日：2019-06-17

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Hong Liu ,  Hongruo Yun ,  Xiaomei Ge ,  Zhiyuan Yang ,  Lianxing Liu ,  Pengbo Zhang ,  Yixiang Xu ,  Shan Li ,  Lucas Horan

IPC: C07K16/00 ,  A61P35/00 ,  C07H21/04 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C12N5/02 ,  C12N15/00 ,  G01N33/574

CPC classification number: C07K16/3069 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2809 ,  G01N33/57434 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to PSMA (e.g., PSMA expressed on the surface of a cell). Also provided are methods of making and using these constructs.

公开(公告)号：US11827672B2

公开(公告)日：2023-11-28

申请号：US17043352

申请日：2019-03-29

Applicant: Eureka Therapeutics, Inc.

Inventor： Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Shan Li ,  Yixiang Xu ,  Guangyan Xiong ,  Hongruo Yun ,  Lianxing Liu ,  Xiaomei Ge ,  Shaohua Xu ,  Hong Liu ,  Javier Morales

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/725 ,  A61K39/00 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2809 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  G01N2333/70503

Abstract: Described herein are antibodies (e.g., single chain variable fragment (scFv) antibodies) and constructs comprising antibody moieties that bind to the extracellular domain of CD22 or a portion thereof (e.g., SEQ ID NO: 205 or a portion thereof). Also provided herein are methods of using the same or compositions thereof for the therapeutic treatment of diseases characterized by CD22 expression, in particular, B-cell lymphomas and leukemias.

公开(公告)号：US20230048360A1

公开(公告)日：2023-02-16

申请号：US17817308

申请日：2022-08-03

Applicant: Eureka Therapeutics, Inc.

Inventor： Pengbo ZHANG ,  Yiyang Xu ,  Javier Morales ,  Yoko Nakano ,  Hong Liu ,  Jingyi Xiang ,  Timothy Acker

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  G01N33/574

Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

公开(公告)号：US20220323497A1

公开(公告)日：2022-10-13

申请号：US17628120

申请日：2020-07-24

Applicant: Eureka Therapeutics, Inc.

Inventor： Hongruo YUN ,  Jun Cui ,  Pengbo Zhang ,  Yiyang Xu ,  Lucas Horan ,  Shaohua Xu ,  Guangyan Xiong ,  Shan Li ,  Yixiang Xu ,  Bradley Austin Heller ,  Hongbing Zhang ,  Hong Liu

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/62 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  A61P35/00

Abstract: Described herein are immune cells comprising: a chimeric antigen receptor (CAR) that comprises (i) an extracellular target-binding domain comprising an antibody moiety; (ii) a transmembrane domain; and (iii) a primary signaling domain, and a chimeric stimulating receptor (CSR) that comprises (i) a ligand-binding module that is capable of binding or interacting with a target ligand; (ii) a transmembrane domain; and (iii) a CD30 costimulatory domain, in which the CSR in the immune cells lacks a functional primary signaling domain. Also provided herein are methods of using the same or compositions thereof for therapeutic treatment of cancers (e.g., hematological cancers or solid tumor cancers).

公开(公告)号：US11447564B2

公开(公告)日：2022-09-20

申请号：US16608377

申请日：2018-04-24

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Pengbo Zhang ,  Yiyang Xu ,  Javier Morales ,  Yoko Nakano ,  Hong Liu ,  Jingyi Xiang ,  Timothy Acker

IPC: C07K16/30 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  G01N33/574 ,  A61K39/00

Abstract: The present application provides constructs comprising an antibody moiety specifically recognizing Glypican 3 (GPC3), such as a cell surface-bound GPC3. Also provided are methods of making and using these constructs.

公开(公告)号：US10301388B2

公开(公告)日：2019-05-28

申请号：US15840870

申请日：2017-12-13

Applicant: Eureka Therapeutics, Inc.

Inventor： Hong Liu ,  Jingwei Lu ,  Zhiyuan Yang ,  Li Long ,  Neal Cheng

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  A61P35/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/30 ,  A61K39/00 ,  A61K38/00

Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

公开(公告)号：US10098951B2

公开(公告)日：2018-10-16

申请号：US15829793

申请日：2017-12-01

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Jingwei Lu ,  Zhiyuan Yang ,  Cheng Liu ,  Hong Liu ,  Yiyang Xu ,  Su Yan ,  Vivien Wai-Fan Chan ,  Lucas Horan

IPC: C07K16/00 ,  A61K39/395 ,  A61K35/17 ,  C12N15/62 ,  C07K14/725 ,  C07K16/28 ,  A61K38/00 ,  A61K39/00

Abstract: The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

公开(公告)号：US20180148503A1

公开(公告)日：2018-05-31

申请号：US15817673

申请日：2017-11-20

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EUREKA THERAPEUTICS, INC.

Inventor： David A. Scheinberg ,  Tao Dao ,  Cheng Liu ,  Hong Liu ,  Yiyang Xu ,  Su Yan

IPC: C07K16/28 ,  A61K47/68 ,  G01N33/574

CPC classification number: C07K16/28 ,  A61K39/0011 ,  A61K47/6849 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/00 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/74 ,  G01N33/57492 ,  G01N2333/705

Abstract: The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL). The antibodies or antigen binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.

公开(公告)号：US11965021B2

公开(公告)日：2024-04-23

申请号：US16608366

申请日：2018-04-24

Applicant: EUREKA THERAPEUTICS, INC.

Inventor： Hong Liu ,  Pengbo Zhang ,  Lucas Horan ,  Yiyang Xu ,  Binnaz K. Staley ,  Lianxing Liu ,  Hongruo Yun

IPC: C07K14/705 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  A61K38/00

CPC classification number: C07K16/2803 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2887 ,  C07K16/303 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells.

公开(公告)号：US11168150B2

公开(公告)日：2021-11-09

申请号：US16665708

申请日：2019-10-28

Applicant: Memorial Sloan Kettering Cancer Center ,  Eureka Therapeutics, Inc.

Inventor： Nai-Kong V. Cheung ,  Mahiuddin Ahmed ,  Andres Lopez-Albaitero ,  Cheng Liu ,  Su Yan ,  Jingyi Xiang ,  Hong Liu

IPC: C07K16/08 ,  C07K16/46 ,  C07K16/28 ,  G01N33/68 ,  A61K39/00

Abstract: Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.